Poxel announces preclinical outcomes on PXL770 for NASH Combinations
Category: #health  By Pankaj Singh  Date: 2020-05-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Poxel announces preclinical outcomes on PXL770 for NASH Combinations

Poxel SA, the France-based dynamic biopharmaceutical firm developing advanced drugs for metabolic diseases, has reportedly announced the preclinical outcomes for PXL770, the main molecule in its AMPK (adenosine monophosphate-activated protein kinase) platform.

Reportedly, the molecule was assessed in a rodent non-alcoholic steatohepatitis (NASH) model together with other main agents in development, including obeticholic acid (FXR agonist), semaglutide (GLP-1 receptor agonist), and MGL-3196 (thyroid receptor β agonist).

According to sources familiar with the knowledge of the matter, outcomes showed the potential of PXL770 as new NASH therapy that may produce additional benefits when combined with other agents with different mechanisms of action.

Apparently, PXL770 was also assessed in rodent models of DKD (Diabetic Kidney Disease) which also evaluated cardiac dysfunction and ALD (adrenoleukodystrophy / AMN (adrenomyeloneuropathy), a fatal disease characterized by neurodegeneration. These results showed that AMPK activation possibly leads to broader usefulness for other diseases mediated by metabolic pathway dysfunction.

Sources cite that the company conducted these clinical trials to further investigate applications of PXL770 in numerous metabolic diseases. Moreover, all  these clinical trials are in support of Phase 2 clinical study and NASH development program.

Speaking on which, David E. Moller, MD, CSO at Poxel said that AMPK is a convincing pharmaceutical target that has been detected to modulate both inflammatory and metabolic pathways and has the potential to treat numerous rare metabolic and chronic diseases.

Mr. Moller added that new preclinical data indicate the potential of PXL770 to show even better additive or synergistic benefits to treat the main causes of NASH in combination with other agents in development. The company is rather delighted at these new findings indicating the potential of PXL770 and AMPK activation for treating other chronic disorders ranging from most common to uncommon monogenic metabolic disorders, Mr. Moller said.
 

Source Credit - https://www.poxelpharma.com/en_us/news-media/press-releases/detail/152/poxel-announces-program-update-and-preclinical-results-on



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...